KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 18282 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Myelofibrosis symptom assessment form total symptom score version 4.0: measurement properties from the MOMENTUM phase 3 study. PMID 39585603 · Qual Life Res · 2025-Mar The record describes a psychometric validation study of a symptom assessment form within a Phase III trial, not a report of the trial's drug efficacy results. It does not contain the required primary or key secondary time-to-event endpoint data.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Intermittent or Continuous Panitumumab Plus Fluorouracil, Leucovorin, and Irinotecan for First-Line Treatment of RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The IMPROVE Trial. PMID 39576946 · J Clin Oncol · 2025-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Effect of intraperitoneal ropivacaine during and after cytoreductive surgery on time-interval to adjuvant chemotherapy in advanced ovarian cancer: a randomised, double-blind phase III trial. PMID 39572271 · Br J Anaesth · 2025-Mar The trial is a randomized Phase III study with a drug intervention and original results, but the primary endpoint (time to return to intended oncologic therapy) is not a standard time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP) and does not involve Kaplan-Meier analysis or hazard ratios, which are required for inclusion in this cohort.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Quality of life and testosterone recovery after androgen deprivation therapy in high-risk prostate cancer patients: long-term data from a phase III trial. PMID 39565556 · Qual Life Res · 2025-Mar The report is a secondary analysis of a Phase III randomized trial in prostate cancer, focusing on quality of life and testosterone recovery. It does not have a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.) or Kaplan-Meier/HR analysis. Additionally, the intervention (ADT) is standard hormonal therapy, not a novel drug intervention meeting the criteria.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Long-Term Outcomes of Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma With UGN-101, a Mitomycin Reverse Thermal Gel. PMID 39561384 · J Urol · 2025-Mar The record describes a long-term follow-up analysis of a single-arm Phase III trial. It is an original report with drug intervention and oncology setting, but it lacks a randomized comparator and does not report a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.) with Kaplan-Meier or HR. The primary endpoint of the original trial appears to be complete response rate (a binary outcome). Therefore, it does not meet the eligibility criteria for a randomized trial with a time-to-event endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Cost-effectiveness of Enasidenib versus conventional care for older patients with IDH2-mutant refractory/relapsed AML. PMID 39560957 · Leuk Lymphoma · 2025-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Progression to complete retinal pigment epithelium and outer retinal atrophy (cRORA): post hoc analysis of the GATHER1 trial. PMID 39538001 · Graefes Arch Clin Exp Ophthalmol · 2025-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
ONS-5010 (bevacizumab-vikg) Safety and Efficacy in Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration. PMID 39535413 · Ophthalmic Surg Lasers Imaging Retina · 2025-Mar 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Short-course subcutaneous treatment with birch pollen allergoids greatly improves symptom and medication scores in birch allergy. PMID 39520181 · Allergy · 2025-Mar 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Population pharmacokinetics and exposure-response relationships of dostarlimab in primary advanced or recurrent endometrial cancer in part 1 of RUBY. PMID 39520048 · Br J Clin Pharmacol · 2025-Mar The record is from a randomized trial (RUBY) that meets many criteria but does not explicitly state the phase as Phase III/IIIb or Phase II/III in the provided metadata. The deterministic review flagged this as 'phase3_evidence_unclear'. The report's primary focus is pharmacokinetics and exposure-response, not the formal primary efficacy analysis of the trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab Plus Talazoparib in Patients With SLFN11 Positive Extensive-Stage SCLC: S1929. PMID 39505259 · J Thorac Oncol · 2025-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
The SQ tree sublingual immunotherapy tablet is effective and well tolerated in children-A pivotal phase III trial. PMID 39495086 · Allergy · 2025-Mar 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
A phase 3 randomized trial of sulopenem vs. ertapenem in patients with complicated intra-abdominal infections. PMID 39491784 · Clin Microbiol Infect · 2025-Mar 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Cost-Utility Analysis of Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin Chemotherapy Regimen in Comparison With Gemcitabine and Cisplatin Chemotherapy Regimen in the Treatment of Patients With Muscle Invasive Bladder Cancer in Iran. PMID 39480370 · Value Health Reg Issues · 2025-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Efficacy of ultrasound-guided bilateral rectus sheath block vs. local anesthetic infiltration in gynecologic oncology patients undergoing midline laparotomy: a triple-blinded randomized controlled trial. PMID 39480232 · Minerva Anestesiol · 2025-Mar The record describes a randomized controlled trial comparing two local anesthetic techniques for postoperative pain management in gynecologic oncology surgery. While it is a randomized trial in human oncology patients, it does not meet several key eligibility criteria: the phase is not established as Phase III/IIIb or Phase II/III, the intervention is a non-drug-only procedural technique (ultrasound-guided rectus sheath block vs. local anesthetic wound infiltration), and the primary endpoints are pain scores and analgesic consumption, which are not time-to-event efficacy outcomes (e.g., OS, PFS, DFS, EFS, RFS, TTP) with Kaplan-Meier or HR reporting.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Statin use and oncological outcomes in a propensity-matched cohort of nonmetastatic castration resistant prostate cancer patients of the ARAMIS trial. PMID 39477770 · Urol Oncol · 2025-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
An international multicentre randomised controlled trial of en bloc resection of bladder tumour vs conventional transurethral resection of bladder tumour: first results of the en bloc resection of urothelium carcinoma of the bladder (EBRUC) II trial. PMID 39462182 · BJU Int · 2025-Mar This is an original, randomized, oncology trial reporting primary results. However, it is excluded because it does not involve a drug-containing intervention (it compares surgical techniques) and does not report a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, with KM or HR). The 'recurrence rates' mentioned are not presented as KM curves or with a hazard ratio.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The effect of Plasmodium falciparum exposure and maternal anti-circumsporozoite protein antibodies on responses to RTS,S/AS01E vaccination in infants and children: an ancillary observational immunological study to a phase 3, randomised clinical trial. PMID 39461358 · Lancet Infect Dis · 2025-Mar 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Immunogenicity of a booster dose of a bivalent (Asp614Gly and omicron BA.4/5 variant) self-amplifying mRNA SARS-CoV-2 booster vaccine versus the BNT162b2 omicron BA.4/5 mRNA vaccine: a randomised phase 3 trial. PMID 39461355 · Lancet Infect Dis · 2025-Mar 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Exposure-Response Analysis of Tofacitinib in Active Psoriatic Arthritis: Results from Two Phase 3 Studies. PMID 39453735 · J Clin Pharmacol · 2025-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Immediate effects of propofol on mood: a randomized comparison of two doses in a cohort with depression. PMID 39417860 · Psychopharmacology (Berl) · 2025-Mar 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Exposure-Efficacy Analysis and Dopamine D2 Receptor Occupancy in Adults with Schizophrenia after Treatment with the Monthly Intramuscular Injectable Risperidone ISM. PMID 39417209 · J Clin Pharmacol · 2025-Mar 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
A Phase II/III multicenter randomized single blind non-inferiority immunogenicity and safety study of TeddyVac™ vaccine of Human Biologicals Institute in healthy subjects of 10 years to 60 years of age. PMID 39378070 · Infect Dis (Lond) · 2025-Mar 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Introducing new antibiotics for multidrug-resistant bacteria: obstacles and the way forward. PMID 39374649 · Clin Microbiol Infect · 2025-Mar 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Re: Peritoneal Flap for Lymphocele Prophylaxis Following Robotic-assisted Radical Prostatectomy with Lymph Node Dissection: The Randomised Controlled Phase 3 PELYCAN Trial. PMID 39368904 · Eur Urol · 2025-Mar 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Re: Long-term Analysis of NRG Oncology RTOG 0415: A Randomized Phase III Noninferiority Study Comparing Two Fractionation Schedules in Patients with Low-Risk Prostate Cancer. PMID 39332930 · Eur Urol · 2025-Mar Oncology human randomized Phase III trial with original result, but excluded due to lack of time-to-event endpoint signal and apparent non-drug-only intervention (radiation fractionation comparison).
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Prostate Cancer-related Events in Patients with Synchronous Metastatic Hormone-sensitive Prostate Cancer Treated with Androgen Deprivation Therapy with and Without Concurrent Radiation Therapy to the Prostate; Data from the HORRAD Trial. PMID 39304427 · Eur Urol · 2025-Mar The report describes a secondary analysis of a randomized controlled trial in oncology. While it is human, oncology, randomized, and reports a time-to-event endpoint (local event-free survival), it lacks a drug-containing intervention (radiotherapy is a non-drug intervention) and the primary endpoint is not a key efficacy endpoint (OS, PFS, DFS, etc.). Therefore, it does not meet all eligibility criteria.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Ten-Year Survivals of Right Thoracic vs Left Thoracic Approach for Esophageal Cancer. PMID 39293749 · Ann Thorac Surg · 2025-Mar The study is a randomized trial in human oncology with primary time-to-event endpoints, but it compares two surgical approaches (right vs. left thoracic) and does not involve a drug-containing intervention. The phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided metadata.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Adjuvant immunotherapy in high-risk muscle invasive urothelial carcinoma: A systematic review and meta-analysis of randomized clinical trials. PMID 39289120 · Urol Oncol · 2025-Mar 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Hypofractionated Dose Escalation Radiotherapy for High-Risk Prostate Cancer: the survival analysis of the Prostate Cancer Study-5 (PCS-5), a GROUQ-led phase III trial. PMID 39271420 · Eur Urol · 2025-Mar The trial meets criteria for oncology, human, randomized, Phase III, time-to-event endpoint, and original result, but the intervention compares radiotherapy fractionation schedules (both with identical androgen suppression), not a drug-containing vs. non-drug or drug-containing intervention. Therefore, it is ineligible due to lack of a drug intervention.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
PRRT in high-grade digestive neuroendocrine neoplasms (NET G3 and NEC). PMID 39243213 · J Neuroendocrinol · 2025-Mar 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Effects of fremanezumab on migraine-associated symptoms and medication use in Japanese and Korean patients with episodic migraine: Exploratory endpoint analysis of a multicenter, randomized, double-blind, placebo-controlled trial. PMID 39221611 · Headache · 2025-Mar 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Comparing Analytical Methods for Composite End Points in Clinical Trials: Insights from the Vericiguat Global Study in Subjects with Heart Failure With Reduced Ejection Fraction Trial. PMID 39182825 · J Card Fail · 2025-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Robotic-assisted versus conventional laparoscopic surgery for endometrial cancer: long-term results of a randomized controlled trial. PMID 39181495 · Am J Obstet Gynecol · 2025-Mar 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Tebentafusp Induces a T-Cell-Driven Rash in Melanocyte-Bearing Skin as an Adverse Event Consistent with the Mechanism of Action. PMID 39019150 · J Invest Dermatol · 2025-Mar This is a secondary analysis of a Phase III RCT focusing on an adverse event mechanism, not the primary time-to-event efficacy report.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A budget impact analysis of a digital monitoring solution in patients treated with oral anticancer agents: a medico-economic analysis of the randomized phase 3 CAPRI trial. PMID 38937329 · Eur J Health Econ · 2025-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Favorable Clinical Outcomes After Humeral Head Depressor Muscle Coactivation Training With EMG for Patients With Arthroscopic Rotator Cuff Repair: A Randomized Controlled Trial. PMID 38499998 · Sports Health · 2025-Mar 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and safety of concurrent radiotherapy and chemotherapy for locally advanced esophageal squamous cell carcinoma: a randomized controlled trial. PMID 40672085 · J Gastrointest Oncol · 2025-Jun-30 The trial is an oncology RCT with drug intervention and time-to-event endpoints (OS, PFS), but the phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided metadata or abstract. The deterministic review code 'phase3_evidence_unclear' indicates uncertainty. Without explicit phase information, eligibility cannot be confirmed.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Treatment discontinuation associated with perioperative toxicity of FLOT versus XELOX chemotherapy in patients with resectable gastric cancer: prospective randomized trial (PECORINO). PMID 40672074 · J Gastrointest Oncol · 2025-Jun-30 The study is a randomized, drug-intervention trial in oncology with a time-to-event secondary endpoint (PFS) and original results. However, the trial phase is not explicitly established as Phase III/IIIb or Phase II/III in the provided metadata, and the primary endpoint is treatment adherence, not an efficacy endpoint as required for inclusion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Comparison of efficacy and safety of a proposed biosimilar QL1206 with reference denosumab in patients with bone metastasis from breast cancer: A subgroup analysis of a randomized, double-blinded phase III study. PMID 40642487 · Chin J Cancer Res · 2025-Jun-30 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Efficacy of mailed surveillance invitations and telephone patient navigation to improve hepatocellular carcinoma surveillance uptake: study protocol of VIGILANT-a single-centre, two-arm randomised controlled trial. PMID 40588390 · BMJ Open · 2025-Jun-30 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
A mobile supportive care app for patients with metastatic lung cancer: the Lung Cancer App (LuCApp) randomized controlled trial. PMID 40586961 · Support Care Cancer · 2025-Jun-30 The study is a randomized trial in oncology with a time-to-event endpoint, but it does not involve a drug-containing intervention (it tests a mobile app for symptom monitoring) and the trial phase is not explicitly stated as Phase III/IIIb or Phase II/III.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy and safety of daprodustat in patients on peritoneal dialysis in the ASCEND-D trial. PMID 39817409 · Nephrol Dial Transplant · 2025-Jun-30 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Targeting insulin-like growth factor-1 (IGF-1) by using metformin in non-diabetic metastatic breast cancer female patients: a randomized controlled trial. PMID 40579605 · Cancer Chemother Pharmacol · 2025-Jun-28 The abstract describes a randomized trial in metastatic breast cancer with a drug intervention (metformin + chemotherapy) and reports original results. However, it does not report a time-to-event efficacy endpoint (e.g., OS, PFS, DFS, etc.) or Kaplan-Meier analysis. The primary outcome appears to be IGF-1 level changes, and the secondary outcome is disease progression (a binary outcome), not a time-to-event endpoint. Therefore, it does not meet the key criterion for inclusion in an oncology Kaplan-Meier digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Once-weekly insulin efsitora alfa versus once-daily insulin glargine U100 in adults with type 2 diabetes treated with basal and prandial insulin (QWINT-4): a phase 3, randomised, non-inferiority trial. PMID 40562048 · Lancet · 2025-Jun-28 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 2 diabetes currently treated with basal insulin (QWINT-3): a phase 3, randomised, non-inferiority trial. PMID 40562047 · Lancet · 2025-Jun-28 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Phase 2/3 study evaluating safety, immunogenicity, and noninferiority of single booster dose of AVX/COVID-12 vaccine. PMID 40577471 · Sci Adv · 2025-Jun-27 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Final Results of ERBIMOX: A Randomized Phase II Study of Modified FOLFOX7 With or Without Cetuximab as First-Line Treatment for KRAS Wild-type Metastatic Colorectal Cancer. PMID 40571867 · J Gastrointest Cancer · 2025-Jun-27 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Adjuvant Chemotherapy for Gastric Cancer may Worsen Prognosis in Elderly Women: Retrospective Analysis of Individual Patient Data from the CLASSIC Study. PMID 40571773 · J Gastrointest Cancer · 2025-Jun-27 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Selective neoadjuvant therapy of rectal cancer patients (SELREC): study protocol for a European randomised controlled, open, multicentre non-inferiority trial. PMID 40578870 · BMJ Open · 2025-Jun-26 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -